| Formulary Amendments |
| Last updated: 20th November 2024 |
| Chapter |
Change |
Traffic light
status |
Reason for change |
| 04.03.01 |
Trimipramine now not to be initiated for new patients and deprescribed in existing patients where possible. |
 |
NENC Medicines Committee (October 2024) |
| 18.08.03 |
Silk garments not approved for use |
|
NENC Medicines Committee (October 2024) |
| 10.03.02 |
Rubefacients not approved for use |
|
NENC Medicines Committee (October 2024) |
| 02.05.05.01 |
Perindopril Arginine not approved for use |
|
NENC Medicines Committee (October 2024) |
| 02.12 |
Omega-3 Fatty acid compounds (except Vazkepa) not approved for use |
|
NENC Medicines Committee (October 2024) |
| 09 |
Lutein and Antioxidants preparations not approved for use |
|
NENC Medicines Committee (October 2024) |
| 09 |
Glucosamine and Chondroitin not approved for use. |
|
NENC Medicines Committee (October 2024) |
| 02.05.04 |
Doxazosin MR not approved for use. |
|
NENC Medicines Committee (October 2024) |
| 04.03.01 |
Dosulepin now not to be initiated for new patients and deprescribed in existing patients where possible. |
|
NENC Medicines Committee (October 2024) |
| 04.07.01 |
Co-proxamol now classed as a medicines of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 13.02.01 |
Bath and shower preparations for dry and pruritic skin conditions classed as medicines of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 02.05.05.03 |
Aliskiren now classed as a medicine of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 05.02.01 |
Off label indication for treatment of non-invasive fungal infections using the voriconazole 100mg tablets ONLY |
 |
NENC Medicines Committee (October 2024) |
| 02.08.02 |
Following statement added to all DOAC listings: "In the absence of a specific clinical reason to select a particular DOAC, choose the most effective DOAC first. Rivaroxaban 'cost effective once daily for non-valvular AF' and Apixaban 'cost effective twice daily choice for non-valvular AF' " |
|
NENC Medicines Committee (October 2024) |
| 13.04.01 |
Removal of calcipotriol scalp solution as now discontinued |
|
NENC Medicines Committee (October 2024) |
| 06.04.02 |
Removal of tradename (Nebido) from testosterone undecanoate 1g/4ml as generics now available |
|
NENC Medicines Committee (October 2024) |
| 01.06.07 |
Prucalopride RAG status changed from GREEN to GREEN+ |
|
NENC Medicines Committee (October 2024) |
| 07.02.01 |
Removal of trademark from estriol 1mg/g (0.1%) cream and clarification of dosage statement |
|
NENC Medicines Committee (October 2024) |
| 01 |
Atropine 500microgram in 5ml mixture removed from formulary |
|
NENC Medicines Committee (October 2024) |
| 11.06 |
Latanoprost 0.005% with Timolol 0.5% eye drops preservative free (Fixapost) added as a PF option |
 |
NENC Medicines Committee (October 2024) |
| 04.06 |
Additional off-license indication (use in children under 12yrs / longer term use, when required, for the prevention of nausea and vomiting in paediatric patients undergoing haematopoietic stem cell transplantation (HSCT)) added to aprepitant 80mg and 125mg capsules |
 |
NENC Medicines Committee (October 2024) |
| 04.10.02 |
Smoking Cessation Therapy entry to replace individual NRT products |
|
NENC Medicines Committee (October 2024) |
| 04.12 |
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |
|
NICE TA984 |
| 08.01.05 |
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (not recommended) |
|
NICE TA983 |
| 10.01.03 |
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) |
|
NICE TA982 |
| 08.01.05 |
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation |
|
NICE TA979 |
| 11.08.02 |
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion |
|
NICE TA1004 |
| 07.04.02 |
North of Tyne, Gateshead & North Cumbria: Urinary Continence Enablement Products and Devices Formulary 2024 |
|
NENC Guidelines Group (October 2024) |
| 04.07 |
NENC Clinical Pain Network: Position Statement on Chronic Pain Guidelines |
|
NENC Guidelines Group (October 2024) |
| 06.04.01.01 |
NENC ICB-wide Menopause guidance - update |
|
NENC Guidelines Group (October 2024) |
| 09.05.01.03 |
NENC ICB-wide Management of Hypomagnesaemia in adults |
|
NENC Guidelines Group (October 2024) |
| 09.04 |
NENC ICB-wide Guidelines for the appropriate prescribing of Oral Nutritional Supplementation in the management of adults at risk of undernutrition in primary care |
|
NENC Guidelines Group (October 2024) |
| 13.02.01 |
NENC ICB-wide Emollient Prescribing Guideline and Formulary added |
|
NENC Guidelines Group (October 2024) |
| 08.01.05 |
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (not recommended) |
|
NICE TA992 |
| 02.11 |
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B |
|
NICE TA989 |
| 08.01.05 |
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) |
|
NICE TA987 |
| 13.05.03 |
Lebrikizumab for treating moderate to severe atopic dermatitis |
|
NICE TA986 |
| 19 |
QuiremSpheres for treating unresectable advanced hepatocellular carcinoma |
|
NICE TA985 |
| 01.05.03 |
Risankizumab for treating moderately to severely active ulcerative colitis |
|
NICE TA998 |
| 02.05.01 |
Sildenafil - amendment of secondary Raynaud's to Raynaud's |
|
NENC Medicines Committee (August 2024) |
| 02.10.02 |
Tenecteplase for treating acute ischaemic stroke |
|
NICE TA990 |
| 03.09.01 |
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) |
|
NICE TA969 |
| 04.01.01 |
Daridorexant - addition of NHCFT to list of providers |
|
NENC Medicines Committee (August 2024) |
| 04.03.03 |
Fluoxetine 10mg capsules - addition of formulation |
|
NENC Medicines Committee (August 2024) |
| 04.06 |
Doxylamine & pyrodoxine for use in nausea and vomiting in pregnancy |
|
NENC Medicines Committee (August 2024) |
| 04.07.02 |
Morphine sulfate oro-dispersible tablets (Actimorph) added and Sevredol removed |
|
NENC Medicines Committee (August 2024) |
| 04.07.04.02 |
Atogepant for preventing migraine |
|
NICE TA973 |
| 05 |
Addition of link for cellulitis diagnosis and management |
|
NENC Medicines Committee (August 2024) |
| 05.03.01 |
Addition of bictegravir, emtricitabine, tenofovir alafenamide (Biktarvy®) |
|
Correction of missing entry |
| 06.03.02 |
Hydrocortisone oral solution & merged entries |
|
NENC Medicines Committee (August 2024) |
| 06.04.01.02 |
Progesterone - Addition of Utrogestran vaginal capsules and clarification of use in relation to NICE NG25 |
|
NENC Medicines Committee (August 2024) |
| 06.07 |
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome |
|
NICE HST31 |
| 07.04.02 |
Vibegron for treating symptoms of overactive bladder syndrome |
|
NICE TA999 |
| 08.01.05 |
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |
|
NICE TA964 |
| 08.01.05 |
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over |
|
NICE TA977 |
| 08.01.05 |
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
|
NICE TA963 |
| 08.01.05 |
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
|
NICE TA968 |
| 08.01.05 |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over |
|
NICE TA967 |
| 08.01.05 |
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) |
|
NICE TA966 |
| 08.01.05 |
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |
|
NICE TA974 |
| 08.01.05 |
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) |
|
NICE TA976 |
| 08.01.05 |
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) |
|
NICE TA978 |
| 08.02.02 |
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) |
|
NICE TA972 |
| 09.01.01.01 |
Addition of position statement for oral iron supplementation for iron deficiency anaemia |
|
NENC Medicines Committee (August 2024) |
| 10.02.02 |
Quinine Sulfate - addition of 200mg tablets |
|
NENC Medicines Committee (August 2024) |
| 11.04.01 |
Hydroortisone Sodium Phosphate eye drops for patients who require a preservative-free low potency ocular corticosteroid |
|
NENC Medicines Committee (August 2024) |
| 13.05.03 |
Pimecrolimus cream - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
| 13.05.03 |
Tacrolimus ointment - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
| 15.01.01 |
Ketamine in palliative care - changed from Amber to Red |
|
NENC Medicines Committee (August 2024) |
